MedTrace Logo

Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer

NCT00898690 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2013-12-18

No results posted yet for this study

Summary

RATIONALE: DNA analysis of tumor tissue may help doctors predict how patients who receive paclitaxel will respond to treatment.

PURPOSE: This laboratory study is evaluating gene expression in predicting response to paclitaxel in patients with breast cancer.

Conditions

Interventions

GENETIC

cytogenetic analysis

GENETIC

gene expression analysis

GENETIC

microarray analysis

GENETIC

mutation analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

immunohistochemistry staining method

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Carlo M. Croce, MD · Sidney Kimmel Cancer Center at Thomas Jefferson University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00898690 on ClinicalTrials.gov